Online inquiry

IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2328MR)

This product GTTS-WQ2328MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD200 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001004196.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4345
UniProt ID P41217
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2328MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15660MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ11122MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ5498MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ10557MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ5281MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ8536MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu5A8
GTTS-WQ10100MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ10673MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW